Urate-lowering effects of losartan: a meta-analysis of randomised controlled trials and target trial emulation.
Hypertens ResJul 15, 2026 (epub)
Xiaoguang Xu, Ahlam Naeem, Amber Emmett et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis of six randomized controlled trials assessed the urate-lowering effects of losartan in hypertensive patients. The study included 1119 patients treated with losartan and 1093 controls, revealing a reduction in serum urate levels by approximately 0.29 mg/dL compared to placebo (95% CI: -0.46 to -0.12, p = 0.0009).
Key findings
- Losartan reduced serum urate levels by approximately 0.29 mg/dL compared to placebo.
- In a target trial emulation, losartan-treated individuals showed a reduction of approximately 0.35 mg/dL.
- The meta-analysis included 1119 losartan-treated patients and 1093 controls.
Why it matters
Understanding the urate-lowering effects of antihypertensive medications like losartan is crucial for managing patients at risk of hyperuricaemia and gout, particularly those on diuretics.